Peak Bio IncOver The Counter Market:PKBO
- LAST PRICE0.0052
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0052
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Peak Bio Inc | 117.7K | 0.0x | --- |
AVAX Technologies Inc | 14.3K | 0.0x | --- |
Viropro Inc | 1.2K | 0.0x | --- |
EPIRUS Biopharmaceuticals Inc | 30.0 | 0.0x | --- |
Corix Bioscience Inc | 20.0 | 0.0x | --- |
Applied Biosciences Corp | 4.4K | 0.0x | --- |
Company Information
Peak Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on commercializing therapeutics that aim to improve and address unmet medical needs for patients with inflammatory, rare and specialty diseases and cancer. The Company’s lead product candidate, PHP-303, is a small molecule, fifth generation, phase II clinical-ready neutrophil elastase (NE) inhibitor (NEI). PHP-303 is an oral, once daily, 0.65 nanomolar, selective, small molecule reversible inhibitor of NE designed to inhibit its bioactive form that the Company is developing for the treatment of alpha-1 antitrypsin deficiency (AATD), a genetic disorder that may result in lung disease or liver disease and, potentially, acute respiratory distress syndrome (ARDS). The Company’s advanced platform in oncology utilizes its toxin, PH-1 or Thailanstatin, to generate a pipeline of antibody-drug-conjugates (ADC) product candidates that are differentiated from traditional ADC-based therapies.
Contact Information
- Headquarters
- 4900 Hopyard Road, Suite 100PLEASANTON, CA, United States 94588
- Phone
- 925-463-4800
- Fax
- 845-818-3588
Executives
- Chairman of the Board
- Hoyoung Huh
- Chief Executive Officer, Chief Operating Officer, Company Secretary, Director
- Stephen Lamond
- Acting Chief Financial Officer
- Timothy Cunningham
- Executive Director, Head of Oncology
- Satyajit Mitra
- Director
- Michael Friedman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $117.7K |
|---|---|
Revenue (TTM) | $621.5K |
Shares Outstanding | 22.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.40 |
Book Value | $-0.41 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,537.41% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
